Insider transaction data reveals that Mary T Szela, a member of the board of directors at Absci Corp (NASDAQ:ABSI), has significantly increased her equity position in the company. On June 30, 2026, Szela purchased 12,900 shares of Absci common stock in an open market transaction. The acquisition was executed at a price of $11.54 per share, resulting in a total transaction value of $148,866. This purchase was conducted in strict adherence to Absci's established trading policies. Following the completion of this transaction, Szela's direct ownership of Absci common stock totals 21,300 shares.
The timing of this insider purchase is notable given the stock's recent market performance. ABSI has been trading near its 52-week high of $12.05. Over the past year, the stock has delivered a substantial 319% return. Despite this strong performance, analysis from InvestingPro indicates that the stock currently appears overvalued when measured against its fair value. The platform offers additional insights and a comprehensive Pro Research Report covering ABSI and over 1,400 other US equities.
Concurrent with the insider activity, Absci has reported interim results from the Phase 1/2a HEADLINE study of ABS-201, an investigational non-hormonal anti-prolactin receptor antibody. The trial, which enrolled 32 healthy volunteers, demonstrated favorable safety data with no serious adverse events recorded. These positive outcomes have influenced analyst sentiment regarding the company. H.C. Wainwright has raised its price target for Absci to $16 while maintaining a Buy rating. Similarly, Guggenheim has increased its price target to $15, citing the potential of ABS-201 in the underserved hair loss market.
To further support its drug programs, Absci has announced a $100 million stock offering. This offering involves the pricing of 13.5 million common shares at $7.41 each. The transaction is anticipated to close soon, pending the satisfaction of customary conditions. These developments highlight Absci's strategic focus on advancing its investigational treatments and expanding its financial resources.
The stock price data shows ABSI trading at 11.52 USD, with a change of -0.100 (-0.86%) at the close. In after-hours trading, the stock moved to 11.85 USD, up +0.310 (+2.69%).